Making Cancer Care Smarter | Oncotype IQ® International

Exact Sciences brings the promise of precision medicine
to life with Oncotype IQ, a full suite of genomic tests.

The only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage invasive breast cancer.

Learn More

Read More
The first clinically validated genomic test to provide an individualised prediction of the 10-year risk of local recurrence (DCIS or invasive carcinoma) to help guide treatment decision-making for people diagnosed with ductal carcinoma in situ.

For more information, please visit our U.S. website for Oncotype DX Breast DCIS Score

Learn More

Read More
The test predicts disease aggressiveness to help guide treatment decisions and determine whether active surveillance or invasive treatment is the best course of action.

For more information, please visit our U.S. website for Oncotype DX Genomic Prostate Score

Learn More

Read More
The first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease.

For more information, please visit our U.S. website for Oncotype DX Colon Recurrence Score

Learn More

Read More

Our Genomic Tests

Breast Cancer

Prostate Cancer

Colon Cancer

Exact Sciences' Response to COVID-19

A Letter from our CEO, Kevin Conroy

READ THE LETTER



What Is the Test

The Oncotype DX test reveals the underlying tumour biology to help guide treatment decisions.

Learn More



Prognostic vs. predictive

Only a truly predictive test can identify the right treatment for the right patient

Learn why it matters



TAILORx

TAILORx results eliminate uncertainty around intermediate scores and show that most patients do not benefit from chemotherapy

Get the results



Standard of Care

Only the Oncotype DX Breast Recurrence Score test is incorporated in the four major international guidelines and recommended by two major EU health technology assessment (HTA) bodies.

See the guidelines

Contact Us

Get in Touch



In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc.

Making cancer care smarter.™



This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

Exact Sciences' Response to COVID-19

A Letter from our CEO, Kevin Conroy

Contact Us

Oncotype DX Breast Recurrence Score

Resources